Wallac Oy

The Fetal Medicine Foundation

Other

Perkinelmer Health Sciences, Inc.

Bioscreening & Diagnostics LLC

Kypros Nicolaides

Howard Cuckle

Tarja Ahola

Ray O Bahado-Singh

Jiri D Sonek

Leona Poon

Ray Bahado-Singh

Particular aspects of the invention are methods for assaying metabolite levels in samples from a patient during pregnancy using nuclear magnetic resonance and direct flow injection mass spectrometry. In various methods, the assayed metabolites may be acylcarnitine or one or more of C3-OH (hydroxypropionylcarnitine), C5-OH (C3DC), C10, C5:1-DC (glutaconylcarnitine), C14:1-OH (hydroxytetradecenoylcarnitine) and C14:2-OH. One or more methods also may include measuring nuchal translucency of the fetus. Other methods relate to predicting fetal congenital heart defects in a fetus.

Metabolomic prediction of congenital heart defect during pregnancy, newborn and pediatric stages

The present description relates to a method for determining the risk of a pregnant woman developing a hypertensive disorder, more specifically gestational hyper-tension or late onset preeclampsia. The present description provides methods useful for determining risk that a pregnant individual will develop a hypertensive disorder or condition of pregnancy, such as gestational hypertension, early preeclampsia, late preeclampsia and related disorders. Several useful combinations of biochemical markers and related clinical population studies are described herein. Additionally, it is proposed herein that certain sets of biochemical markers can be used to determine risk of multiple hypertensive disorders in a single screen. The biochemical markers are PlGF, Activin A and optionally P-Selectin.

Methods for determining maternal health risks

The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.

Methods for determining the risk of prenatal complications

Methods for prenatal screening for trisomy 21 employ examination of the fronto-maxillary facial (FMF) angle of a fetus. The methods may comprise obtaining a two or three dimensional image of a fetal face, measuring the FMFangle and/or FMFangle on the image, and comparing the measured FMFangle and/or FMFangle with an FMFangle and/or FMFangle characteristic of chromosomally normal fetuses. A measured FMFangle and/or FMFangle greater than the FMFangle and/or FMFangle characteristic of chromosomally normal fetuses provides an indication of an increased likelihood of the occurrence of trisomy 21 in the fetus.

Methods of prenatal screening for trisomy 21

Growing community of inventors

London, United Kingdom

Kypros Nicolaides